<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">2 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/08/28/3352471/0/en/hutchmed-announces-nmpa-approval-for-atled-fanregratinib-for-the-treatment-of-patients-with-fgfr2-fusion-rearrangement-intrahepatic-cholangiocarcinoma.html">HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma</a>
    </div>

      <div class="me-0 me-md-5">
        Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Proactive Investors</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.proactiveinvestors.co.uk/companies/news/1097128?SNAPI">HUTCHMED shares rise as lung cancer drug trial hits key targets</a>
    </div>

      <div class="me-0 me-md-5">
        Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares rose 4% to 192p after the biopharmaceutical company reported positive top-line results from a late-stage global trial of its lung cancer drug savolitinib. The Phase III SAFFRON study tested savolitinib, sold as Orpathys, in combination with AstraZeneca PLC&#39;s (LSE:AZN, NASDAQ:AZN) Tagrisso in patients with a form of non-small ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/08/17/3345800/0/en/hutchmed-announces-orpathys-plus-tagrisso-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-.html">HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®</a>
    </div>

      <div class="me-0 me-md-5">
        — First global Phase III trial to show significant progression-free and overall survival benefits in this setting —
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 news-box__source-badge">
          <img class="news-box__source-logo" alt="StocksGuide" src="https://stocksguide.com/assets/logos/stocks_guide-94bb1add.svg" />
        </div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a data-turbo-frame="_top" href="https://stocksguide.com/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035#earnings-events-section">Hutchison China MediTech Limited Sponsored ADR Q2 2026 Earnings Call Transcript available</a>
    </div>

      <a data-controller="earnings-news-cta" data-earnings-news-cta-event-id-value="4674644" data-action="click-&gt;earnings-news-cta#open" data-turbo-frame="_top" class="btn btn-outline-primary btn--small border-0 mt-0 px-2" href="https://stocksguide.com/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035?earnings_event_id=4674644">
        Show summary
        <i class="fa fa-arrow-right fa-fw"></i>
</a>  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
      <a data-turbo-frame="_top" href="https://stocksguide.com/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035#earnings-events-section">
        <div class="news-box__logo-frame mb-3 mb-md-0">
          <img class="news-box__logo" alt="Hutchison China MediTech Limited Sponsored ADR" src="https://stocksguide.com/rails/active_storage/blobs/proxy/eyJfcmFpbHMiOnsiZGF0YSI6MTc0OTMsInB1ciI6ImJsb2JfaWQifX0=--ad59368323185aef29c16a673c32357186ee1eed/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035.png" />
          <span class="news-box__logo-label">Earnings Call Transcript</span>
        </div>
</a>  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/07/02/3321131/0/en/HUTCHMED-Announces-NMPA-Approval-for-ORPATHYS-for-the-treatment-of-Gastric-Cancer-Patients-with-MET-Amplification.html">HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification</a>
    </div>

      <div class="me-0 me-md-5">
        First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260623406678/en/Syndio-Acquires-Embrace.ai/">Syndio Acquires Embrace.ai</a>
    </div>

      <div class="me-0 me-md-5">
        SEATTLE--(BUSINESS WIRE)--Syndio, the Decision Intelligence for Pay company, today announced the acquisition of Embrace.ai, an agentic AI company built to deploy AI-driven automation across business workflows. The full Embrace.ai team, led by founders and enterprise software veterans Derek Butts and Seth Halpern, will join Syndio&#39;s product and go-to-market organization. The acquisition bolsters...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/edgewise-therapeutics-announces-positive-top-line-data-from-12-week-phase-2-cirrus-hcm-trial-with-edg-7500-in-obstructive-and-nonobstructive-hypertrophic-cardiomyopathy-hcm-302801108.html">Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)</a>
    </div>

      <div class="me-0 me-md-5">
        – No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, symptoms and functional status across obstructive and nonobstructive HCM  – – EDG-7500 administration continued to be generally well tolerated – – Company to host webcast today at 8:30 a.m. Eastern Ti...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/16/3312225/0/en/isolved-Honors-Top-Performing-Partners-at-Annual-Connect-for-Partners-Event.html">isolved Honors Top-Performing Partners at Annual Connect for Partners Event</a>
    </div>

      <div class="me-0 me-md-5">
        LAS VEGAS, June 15, 2026 (GLOBE NEWSWIRE) -- Connect for Partners – isolved®, a provider of human capital management (HCM) solutions that help organizations recruit, retain and elevate their workforce, proudly recognized top-performing partners during its annual isolved Connect for Partners. Now in its ninth year, Connect for Partners has grown into the premier gathering for the isolved partner...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035/load_more?page=4">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>